ArticleInternational ophthalmology2024
Clinical outcomes of an extended depth-of-focus intraocular lens in patients with glaucoma.
Article in International ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of Clinical Outcomes of an Isofocal Optic-Design Intraocular Lens with Double C-Loop Haptics in Eyes with Glaucoma.Journal of clinical medicine · 2026Article
- Visual outcomes in patients with bilateral early to moderate primary open-angle glaucoma following wavefront-shaping partial-range of field-extend intraocular lens implantation.The British journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeto evaluate the clinical outcomes of a hybrid refractive/extended depth-of-focus intraocular lens (Lucidis; Swiss Advanced Vision, SAV-IOL SA, Neuchâtel, Switzerland) in glaucoma patients and to compare the contrast sensitivity results as regards to method of glaucoma control.
methodsThis retrospective multicenter study included 28 patients with visually impairing cataract and controlled early to moderate primary open angle glaucoma who underwent phacoemulsification and Lucidis intraocular lens implantation during the period from June 2021 to July 2023. Medical records were reviewed for baseline characteristics, severity, adequacy and method of control of glaucoma, details of cataract surgery and postoperative findings. Clinical outcomes were analysed at 3 months postoperatively and included uncorrected and best corrected near, intermediate and distance visual acuities, manifest refraction, contrast sensitivity, and patient satisfaction (adapted from the Catquest-9SF questionnaire).
results42 eyes of 28 patients were included, with a male to female ratio of 1:1.8. There was a highly significant improvement in postoperative uncorrected and best corrected near, intermediate, and distance visual acuities (p < 0.001). Mean postoperative contrast sensitivity was 1.56 ± 0.11 log and there was no significant difference between medically and surgically controlled glaucoma (P = 0.08). There was a highly significant correlation between preoperative mean deviation and postoperative contrast sensitivity (p < 0.001). 26 (92.9%) patients were very satisfied. One (2.4%) eye developed dysphotopsia and no serious complications occurred throughout the study.
conclusionsLucidis IOL is effective and safe in patients with cataract and early to moderate POAG requesting spectacle independence. Adequate glaucoma control, regardless the method of control, and better preoperative mean deviation ensure good clinical outcomes.
trial registrationZU-IRB#11,295-28-11-2023, 28/11/2023 'retrospectively registered'.
Indexed as
Identifiers
39592543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.